We then expected that EZH2 inhibitors may strengthen the efficacy of STM2457 in treating EZH2high m6Ahigh tumors (i.e., advanced PCa types) by further elimination of m6A via downregulation of YTHDF1/METTL14/WTAP along with blocking the multifaceted tumorigenic functions of EZH2. This evidence concerns the gene METTL14 and posterior cortical atrophy.